| abstract |
The present invention relates to a novel immunoglobulin Fc domain variant protein and use thereof. When expressed in the form of a fusion protein with a different biologically active protein, the immunoglobulin Fc domain variant protein according to an embodiment of the present invention not only increases the half-life of the biologically active protein in vivo, but also effectively inhibits effector functions such as ADCC or CDC, thereby allowing unexpected side effects to be minimized. |